Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children

被引:17
作者
Himes, Sarah K. [1 ]
Wu, Julia W. [2 ]
Jacobson, Denise L. [3 ]
Tassiopoulos, Katherine [2 ]
Hazra, Rohan [4 ]
Kacanek, Deborah [3 ]
Van Dyke, Russell B. [5 ]
Rich, Kenneth C. [6 ]
Siberry, George K. [4 ]
Huestis, Marilyn A. [1 ]
机构
[1] NIDA, Chem & Drug Metab Sect, Intramural Res Program, NIH, Baltimore, MD 21224 USA
[2] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA
[4] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Maternal & Pediat Infect Dis Branch, NIH, Bethesda, MD USA
[5] Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA
[6] Univ Illinois, Dept Pediat, Chicago, IL USA
关键词
meconium; tenofovir; antiretroviral; birth; growth; bone; DXA; HIV-exposed uninfected children; HIV-1-INFECTED PREGNANT-WOMEN; DISOPROXIL FUMARATE; MINERAL DENSITY; RHESUS MACAQUES; SAFETY; PHARMACOKINETICS; THERAPY; EMTRICITABINE; TRANSPORTERS; ADOLESCENTS;
D O I
10.1097/INF.0000000000000747
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Maternal tenofovir disoproxil fumarate (TDF) treatment among HIV-infected pregnant women results in fetal tenofovir (TFV) exposure. Fetal TFV toxicity was demonstrated in animals, but most clinical investigations have not observed toxicity in humans. Methods: We evaluated HIV-exposed, uninfected infants in the Surveillance Monitoring for Antiretroviral Therapy Toxicities cohort of the Pediatric HIV/AIDS Cohort Study whose mothers were prescribed TDF for 8 third trimester weeks. Infant dual-energy X-ray absorptiometry scans were obtained at 0-4 weeks to measure whole body bone mineral content. Meconium TFV concentrations were quantified by liquid chromatography-tandem mass spectrometry. Results: Fifty-eight TFV-exposed infants had meconium TFV quantified. Detectable concentrations were 11-48,100ng/g; 3 infants had undetectable concentrations. Maternal TDF prescription duration ranged from 8 to 41 gestational weeks; infant gestational ages were 36-41 weeks. Meconium TFV concentrations were not correlated with TFV exposure duration or timing and did not vary by concomitant prescription of protease inhibitors. Increased meconium TFV concentrations were associated with greater gestational ages ( = 0.29, P = 0.03) and lower maternal plasma HIV RNA before delivery ( = -0.29, P = 0.04). Meconium TFV concentrations were not associated with infant weight, length (n = 58) or bone mineral content (n = 49). Conclusions: For the first time, we explored associations between meconium TFV concentrations and infant growth and bone measurements; we did not observe a meconium concentration-dependent relationship for these infant outcomes. These findings support other clinical research failing to show dose-response relationships for growth and bone outcomes among intrauterine TFV-exposed infants. High meconium TFV concentrations correlated with low maternal viral load, suggesting maternal TDF adherence significantly contributes to meconium TFV concentrations.
引用
收藏
页码:851 / 857
页数:7
相关论文
共 51 条
  • [31] POSTMORTEM DRUG ANALYSIS OF MECONIUM IN EARLY-GESTATION HUMAN FETUSES EXPOSED TO COCAINE - CLINICAL IMPLICATIONS
    OSTREA, EM
    ROMERO, A
    KNAPP, DK
    OSTREA, AR
    LUCENA, JE
    UTARNACHITT, RB
    [J]. JOURNAL OF PEDIATRICS, 1994, 124 (03) : 477 - 479
  • [32] Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus
    Purdy, Julia B.
    Gafni, Rachel I.
    Reynolds, James C.
    Zeichner, Steven
    Hazra, Rohan
    [J]. JOURNAL OF PEDIATRICS, 2008, 152 (04) : 582 - 584
  • [33] Tenofovir Treatment Duration Predicts Proteinuria in a Multiethnic United States Cohort of Children and Adolescents With Perinatal HIV-1 Infection
    Purswani, Murli
    Patel, Kunjal
    Kopp, Jeffrey B.
    Seage, George R., III
    Chernoff, Miriam C.
    Hazra, Rohan
    Siberry, George K.
    Mofenson, Lynne M.
    Scott, Gwendolyn B.
    Van Dyke, Russell B.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2013, 32 (05) : 495 - 500
  • [34] Ransom CE, 2013, JAIDS-J ACQ IMM DEF, V64, P374, DOI 10.1097/QAI.0b013e3182a7adb2
  • [35] Comparison of Bone and Renal Effects In HIV-infected Adults Switching to Abacavir or Tenofovir Based Therapy in a Randomized Trial
    Rasmussen, Thomas A.
    Jensen, Danny
    Tolstrup, Martin
    Nielsen, Ulla S.
    Erlandsen, Erland J.
    Birn, Henrik
    Ostergaard, Lars
    Langdahl, Bente L.
    Laursen, Alex L.
    [J]. PLOS ONE, 2012, 7 (03):
  • [36] REYNOLDS LP, 1995, J ANIM SCI, V73, P1839
  • [37] Evidence for altered placental blood flow and vascularity in compromised pregnancies
    Reynolds, LP
    Caton, JS
    Redmer, DA
    Grazul-Bilska, AT
    Vonnahme, KA
    Borowicz, PP
    Luther, JS
    Wallace, JM
    Wu, G
    Spencer, TE
    [J]. JOURNAL OF PHYSIOLOGY-LONDON, 2006, 572 (01): : 51 - 58
  • [38] MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs
    Schuetz, JD
    Connelly, MC
    Sun, DX
    Paibir, SG
    Flynn, PM
    Srinivas, RV
    Kumar, A
    Fridland, A
    [J]. NATURE MEDICINE, 1999, 5 (09) : 1048 - 1051
  • [39] Siberry G, 2014, C RETR OPP INF MARCH
  • [40] Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants
    Siberry, George K.
    Williams, Paige L.
    Mendez, Hermann
    Seage, George R., III
    Jacobson, Denise L.
    Hazra, Rohan
    Rich, Kenneth C.
    Griner, Raymond
    Tassiopoulos, Katherine
    Kacanek, Deborah
    Mofenson, Lynne M.
    Miller, Tracie
    DiMeglio, Linda A.
    Watts, D. Heather
    [J]. AIDS, 2012, 26 (09) : 1151 - 1159